Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAnnovis Bio Inc

Annovis Bio Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.8779 USD 0.03 ( 3.91%)
Last update at 2026-11-09T15:22:00Z
VOLUME
2179956
Market Cap
47.80M

Momentum Score

…

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.83
Low
0.99
High
52 Week Price Range
1.09
Low
5.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.84
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-703.68%
Net Debt
-19532.34M
ROCE
-170.21%
Diluted EPS TTM
-1.72

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -28.85M -24.59M -56.20M -25.33M -14.49M
Net income -28.85M -24.59M -56.20M -25.15M -14.44M
Selling general administrative 4479.65M 6.70M 6.24M 9.00M 6.06M
Selling and marketing expenses - 0.10M 0.10M - -
Ebit - - -45.04M - -14.54M
Ebitda -29.70M -26.69M -45.03M -25.51M -14.50M
Depreciation and amortization - - 0.00M - 0.04M
Non operating income net other - - - - 0.04M
Operating income -29.70M -26.69M -45.03M -25.51M -14.54M
Other operating expenses 29.70M 26.69M 45.03M 25.51M 14.50M
Interest expense - 1.85M - -0.18M 0.01M
Interest income 0.70M 0.33M 0.68M 0.18M 0.01M
Net interest income 0.70M -1.52M 0.68M 0.18M 0.01M
Income tax expense - -24565.78M -0.05M -0.18M -0.05M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 29.70M 26.69M 45.03M 25.51M 14.50M
Total other income expense net 0.84M 2.10M -11.17M 0.18M 0.05M
Net income from continuing ops -28.85M -24.59M -41.72M -25.33M -14.49M
Net income applicable to common shares - - - - -14.49M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 21.08M 13.93M 10.21M 36.02M 46.00M
Other current assets -19511.26M 3.37M 4.45M 7644.38M 315.46M
Total liab 4.23M 4.62M 17.96M 7.70M 1.51M
Total stockholder equity 16.85M 9.31M -7.75M 28.32M 44.49M
Other current liab 1.04M 1.58M 2.99M 3.74M 0.82M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -163.70M -134.85M -110.26M -54.05M -28.73M
Other assets 1549.29M 3373.72M - - -
Cash 19532.34M 10.55M 5.75M 28.38M 45.69M
Total current liabilities 3.64M 3.88M 4.28M 7.70M 1.51M
Net debt -19532.34M -10.55M -5.75M -28.38M -45.69M
Other stockholder equity 180.55M 144.16M 102.51M 82.38M 73.22M
Total current assets 21.08M 13.93M 10.21M 36.02M 46.00M
Net tangible assets - - - - 44.49M
Short term investments - 10541.36M - - -
Accounts payable 2.59M 2.31M 1.29M 3.96M 0.69M
Common stock total equity - - - - 0.00M
Retained earnings total equity - - - - -28.73M
Non currrent assets other 1549.29M - - - -
Non current assets total 1549.29M 13911.71M 0.00M 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Change to liabilities - - - - 0.93M
Total cash from financing activities 34600.12M 26691.80M 17.34M 0.00M 46.74M
Change to operating activities - - - - 0.31M
Net income -28854.20M -24590.38M -56.20M -25.33M -14.49M
Change in cash 8980.42M 4797.20M -22.62M -17.31M 37.61M
Begin period cash flow 10551.92M 5754.72M 28.38M 45.69M 8.07M
End period cash flow 19532.34M 10551.92M 5.75M 28.38M 45.69M
Total cash from operating activities -25619.70M -21894.60M -39.97M -17.31M -9.13M
Issuance of capital stock 34.60M 18.67M 8.57M 0.00M 46.65M
Sale purchase of stock - - - - 46.74M
Other cashflows from financing activities 34565.52M 26673.13M 0.46M 0.00M 0.10M
Change to netincome - - - - 4.70M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Cash flows other operating - - - - -0.27M
Cash and cash equivalents changes - - - - 37.61M
Change in working capital 1.58M 0.68M -0.23M -1.14M 0.66M
Stock based compensation 1797.68M 3836.77M 4.63M 9.15M 4.70M
Other non cash items 1435.24M -1141.68M 11.84M - 14472.64M
Free cash flow -25619.70M -21894.60M -39.97M -17.31M -9.13M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ANVS
Annovis Bio Inc		 0.03
3.91%		 0.88 - - - 25.18 -3.57
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Annovis Bio Inc

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

101 Lindenwood Drive, Malvern, PA, United States, 19355

484 875 3192

https://www.annovisbio.com

7

Name Title Year Born
Dr. Maria L. Maccecchini Ph.D. Founder, CEO, Pres & Exec. Director 1951
Mr. Henry Hagopian III, M.B.A. Chief Financial Officer 1968
Dr. Cheng Fang Ph.D. Sr. VP of R&D NA
Ms. Eve M. Damiano M.S., RAC Sr. VP of Regulatory Operations NA
Dr. Maria L. Maccecchini Ph.D. Founder, Acting CFO, CEO, President & Executive Director 1951
Dr. Cheng Fang Ph.D. Senior Vice President of Research & Development NA
Ms. Eve M. Damiano M.S., RAC Senior Vice President of Regulatory Operations NA
Mr. Blake Jensen M.B.A. Head of Quality NA
Ms. Hilda Maibach Senior Vice President of Statistics NA
Dr. Cheng Fang Ph.D. Chief Scientific Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…